SIGLEC10 and B-cell chronic lymphocytic leukemia: Among 35 cases with confirmed IgV‐mutated, and 18 cases with IgV‐unmutated status, we observed a high variation in the Siglec‐10 surface expression level, but overall observed a significant downmodulation of Siglec‐10 on the surface of CLL cells compared to the corresponding normal residual B cell population, independent of the IgV‐mutation status of the tumor (Fig 8A), or BINET stage of the patient (Fig EV5B).